Second primary malignancies represent small proportion of adverse events after CAR T-cell therapy
by Elana GotkineSecond primary malignancies (SPMs) represent a small proportion of adverse events (AEs) reported by patients receiving chimeric antigen receptor T-cell (CAR T-cell) therapy, according
Updated on: March 30,2024
0

Second primary malignancies represent small proportion of adverse events after CAR T-cell therapy
by Elana GotkineSecond primary malignancies (SPMs) represent a small proportion of adverse events (AEs) reported by patients receiving chimeric antigen receptor T-cell (CAR T-cell) therapy, according
Updated on:March 30,2024
0
